Overwhelming evidence indicates that cancer is a genetic disease caused by the accumulation of mutations in oncogenes and tumor suppressor genes. It is also increasingly apparent, however, that cancer depends not only on mutations in these coding genes but also on alterations in the large class of non-coding RNAs. Here, we report that one such long non-coding RNA, TRPM2-AS, an antisense transcript of TRPM2, which encodes an oxidative stress-activated ion channel, is overexpressed in prostate cancer (PCa). The high expression of TRPM2-AS and its related gene signature were found to be linked to poor clinical outcome, with the related gene signature working also independently of the patient's Gleason score. Mechanistically, TRPM2-AS knockdown led to PCa cell apoptosis, with a transcriptional profile that indicated an unbearable increase in cellular stress in the dying cells, which was coupled to cell cycle arrest, an increase in intracellular hydrogen peroxide and activation of the sense TRPM2 gene. Moreover, targets of existing drugs and treatments were found to be consistently associated with high TRPM2-AS levels in both targeted cells and patients, ultimately suggesting that the measurement of the expression levels of TRPM2-AS allows not only for the early identification of aggressive PCa tumors, but also identifies a subset of at-risk patients who would benefit from currently available, but mostly differently purposed, therapeutic agents.
INTRODUCTION
While prostate cancer (PCa) is today a common diagnosis, several men have indolent tumors that can be safely followed with no need for treatment. 1, 2 However, others present with an aggressive disease course that requires immediate therapeutic intervention. It is, therefore, of paramount importance to determine which tumors, if left untreated, would affect either the quality or quantity of a patient's life. The introduction of the prostate-specific antigen test, while revolutionizing the way PCa is diagnosed and treated, has possibly exacerbated the problem of overdiagnosis and overtreatment, resulting in controversy regarding its use as a screening tool. [3] [4] [5] Hence, there is a strong need for new biomarkers to supplement prostate-specific antigen for the detection and management of PCa.
Studies on higher vertebrate genomes have shown that a large fraction of transcripts and their corresponding RNAs are noncoding RNAs (ncRNAs) that are differentially expressed in many tissues and organs. 6, 7 The role of some ncRNAs has been characterized and it is evident that they are important players in gene regulations and govern normal cell phenotype. 8, 9 The recently discovered class of long ncRNAs has been shown also to be linked to several processes related to cancer, like apoptosis, proliferation, cell cycle progression and cell growth, suggesting a possible role for long ncRNA as novel markers of disease progression or outcome (reviewed in Gutschner and Diederichs 10 ). For instance, the ncRNA HOTAIR (Hox transcript antisense RNA) is overexpressed in breast, colorectal and pancreatic cancer and is a predictor for metastasis formation and associated with a poor prognosis. [11] [12] [13] Similarly, the ncRNA PCa-associated transcript 1 is highly upregulated in a subset of metastatic and high-grade localized PCas, with functional studies showing also a role in cell proliferation. 14 We previously reported that long ncRNA TRPM2-AS, an antisense transcript of the TRPM2 gene, 15 is overexpressed in different tumor types, but no attempt had been made yet to evaluate it as a tumor marker. The first goal of this study was, therefore, to more fully understand the role of TRPM2-AS in the prognosis of PCa. We began by determining whether TRPM2-AS is associated with poor prognosis in a publicly available patient data set. This also allowed us to determine which transcripts and pathways were associated with TRPM2-AS expression, leading to the identification of a gene signature whose prognostic capabilities could then be tested in two additional independent cohorts. TRPM2-AS was also tested as a novel therapeutic target in PCa by inhibiting its expression in human prostate carcinoma cells using RNAi and determining the transcriptome profile of the targeted cells. Identification of significant overlaps among the transcripts that were related to high TRPM2-AS levels in both patients and prostate carcinoma cells allowed us to search for new therapeutic strategies based on existing treatments that target TRPM2-AS or molecules in its pathway.
RESULTS
Quantitative RT-PCR (qRT-PCR) analysis comparing normal prostate samples (11 healthy prostate samples and the immortalized, non-malignant PNT1A prostate epithelial cell line) to tumor samples (13 prostate tumor tissues and the three prostate tumor cell lines DU145, LNCaP and PC3) indicated that TRPM2-AS expression was higher in the diseased samples (Figure 1a and Supplementary Figure S1 ). Mining of aggregate data from 6 recent RNA-seq studies, in which a total of 24 non-tumor prostate samples were compared with 73 prostate tumor specimens, confirmed that the expression of TRPM2-AS was higher in both the tumor tissues and tumor cell lines compared with the non-tumor samples, as shown in Supplementary Table S1 and Supplementary Data. Using microarray analysis, the level of TRPM2-AS was also found to be higher in the tumor samples of an independent cohort 16 (herein referred to as the 'Taylor data set'; Supplementary Figure S2a ). The Taylor data set, which consisted of 150 human PCa samples, 29 normal adjacent prostate samples and 6 prostate Figure 1 . TRPM2-AS is upregulated in PCa, with high TRPM2-AS expression correlating with poor clinical outcome. (a) qRT-PCR analysis of TRPM2-AS expression in the following cDNA samples: 11 prostate samples from healthy control donors and the non-malignant PNT1A prostate cell line (samples C1 through C12); 13 tumor tissues and the 3 prostate tumor cell lines PC3, DU145 and LNCaP (samples T1 through T16). The samples were normalized against C10, with the value of the C10 equal to 1. Gray and black bars represent the non-malignant and tumor samples, respectively. (b) Quantification of TRPM2-AS in PCa samples from the Taylor data set. The quantification values are expressed in arbitrary units, with a value of 1 corresponding to the average TRPM2-AS expression in the healthy prostate samples from this same data set. Samples with low or high TRPM2-AS levels are represented with horizontal, light gray or black bars, respectively. Samples with intermediate TRPM2-AS levels are represented with dark gray bars. The average TRPM2-AS level in the 'low TRPM2-AS' patients was similar to the average TRPM2-AS level in the healthy prostate samples from this same cohort (n = 55), whereas the 'high TRPM2-AS' patients showed a >fourfold increase in their TRPM2-AS level compared with the average level observed for the 'low TRPM2-AS' patients (n = 21). (c) Average values for the clinical variables of the TRPM2-AS-depleted and TRPM2-AS-rich samples in the Taylor data set. (d) Top 20 regulated transcripts in the TRPM2-AS-rich samples from the Taylor data set. (e) Survival curve of the patients from the Sboner data set. The patients were divided into two groups, ind_TRPM2-AS_+ (n = 78) and ind_TRPM2-AS_ − (n = 121), according to their ind_TRPM2-AS expression. (f) Relapse plot of patients from the Glinksy data set carrying either the ind_TRPM2-AS_+ (n = 28) or the ind_TRPM2-AS_ − (n = 39) signature. (g) Survival curve of the patients from the Sboner data set with a Gleason score of 7 and either the ind_TRPM2-AS_+ (n = 37) or the ind_TRPM2-AS_ − (n = 54) signature. (h) Relapse plot of patients from the Taylor data set with a Gleason score of 6-7. The patients were subdivided into two groups according to their ind_TRPM2-AS signature.
tumor cell lines, allowed us also to associate TRPM2-AS expression with clinical parameters. To this purpose, the patients of this data set were initially sorted on the basis of their TRPM2-AS content ( Figure 1b ). Then, the clinical parameters of the patients who had the same average TRPM2-AS content in their tumor samples as that found in the prostate samples from the healthy subjects of this same cohort ('low-TRPM2-AS' patients; average TRPM2-AS content: 1) were compared with the clinical parameters of the patients who had a >fourfold increase in their TRPM2-AS content with respect to the average TRPM2-AS content of the 'low-TRPM2-AS' patients ('high-TRPM2-AS' patients; average TRPM2-AS content: 5.7). This rather robust separation of the samples (P = 2.6E-27) was aimed at minimizing the background, which can be rather high when analyzing the expression of low-abundance RNA, such as TRPM2-AS, in microarray data from heterogeneous clinical samples. 17 The results of this analysis, shown in Figure 1c , indicated that the 'high TRPM2-AS' tumors possessed several indicators of poor prognosis. Accordingly, their biochemical relapse curve was also significantly worse (Supplementary Figure  S2b) . A more standard, but less stringent patient stratification, comparing the top quartile TRPM2-AS expression (average TRPM2-AS content: 0.9) vs the bottom quartile one (average TRPM2-AS content: 4.9), largely confirmed the link between high TRPM2-AS levels and the worsening of several clinical parameters (Supplementary Figure S3 ), demonstrating that this association is robust enough to be detected even when using a less significant TRPM2-AS patient separation (P = 5.4E-18). Differential expression analysis identified 310 upregulated and 186 downregulated transcripts in 'high-TRPM2-AS' samples of the Taylor data set ( Supplementary Table S2 ). A heat map of the top 10 regulated transcripts confirmed the link between a high level of TRPM2-AS and TMRPSS2:ERG fusion by re-identifying several transcripts that are associated with ERG overexpression in PCa, including ERG itself, 18 CRISP3, 19 ANPEP, 20 F5, 20 RLN1, 20 TDRD1 20 and CACNA1D 21 (Figure 1d ). While this associated TRPM2-AS signature (herein named 'ind_TRPM2-AS') only indirectly reflects the level of TRPM2-AS, it is very robust, as it consists of 496 common, readily expressed transcripts that can be promptly used in meta-analyses. TRPM2-AS alone is a single, low-abundance ncRNA, and probes corresponding to TRPM2-AS are present only in the most recent microarray chips, somewhat hampering its quantification, especially in older patient cohorts. The opportunities offered by the ind_TRPM2-AS signature were pursued by analyzing its expression in a second, independent data set consisting of prostate resections from the Swedish Watchful Waiting tumor cohort 22 (herein named the 'Sboner data set'), which consisted of 281 primary tumors. As a result, the clinical parameters of the patients in this data set that were enriched for the ind_TRPM2-AS signature (ind_TRPM2-AS_+) were significantly worse compared with the ind_TRPM2-AS_ − patients, as shown in Supplementary Figure S4 . Accordingly, the survival curve of these patients was also significantly poorer ( Figure 1e ). The relapse curve was found to be significantly different in a third, independent data set consisting of 79 tumor samples 23 (herein named the 'Glinsky data set'), as displayed in Figure 1f . As expected, the re-application of the ind_TRPM2-AS signature to the original Taylor data set readily stratified the patients with different prognostic outcomes ( Supplementary Figures S5a and b ). To determine whether even low-Gleason score patients could be stratified using the ind_TRPM2-AS signature, we calculated the life expectancy of patients from the Sboner data set with a Gleason score of 7 and either the ind_TRPM2-AS_+ or ind_TRPM2-AS_ − signature. Patients with the ind_TRPM2-AS_+ signature showed, in addition to other poor prognostic indicators (Supplementary Figure S6a ), a 1.9-fold higher hazard ratio (95% confidence interval, 1. 15-3.20) . Remarkably, the ind_TRPM2-AS_+ patients from the Taylor data set with a Gleason score ⩽ 7, in addition to displaying a similarly poor prognostic profile (Supplementary Figure S6b ), had a 8.9-fold higher hazard ratio (95% confidence interval, 3.12-25.63). Accordingly, the Kaplan-Meier curves of both patient types were significantly different in both data sets (Figures 1g and h, respectively). Taken together, these data indicate that TRPM2-AS is overexpressed in PCa and that its expression correlates with poor clinical outcome, with its related ind_TRPM2-AS signature working independently of the Gleason score. A multivariate analysis also showed that the ind_TRPM2-AS signature was an independent predictor of PCa-specific mortality in the Sboner data set (Supplementary Figure S7a) , as well as an independent predictor of biochemical recurrence in the Glinsky data set (Supplementary Figure S7b) .
Gene Set Enrichment Analysis (GSEA) 24 of the Sboner data set revealed several gene lists enriched in ind_TRPM2-AS_+ patients ( Supplementary Table S3 ). Examples, respectively shown in Supplementary Figures S8a and e, underline several aggressive traits of these tumors, like a higher tendency to metastasize (Supplementary Figure S8a) , remarkably suggesting that the malignant potential is already encoded in the expression profile of primary ind_TRPM2-AS_+ tumors, and an enhanced proliferation rate (Supplementary Figure S8b ) coupled to resistance to doxorubicin (Supplementary Figure S8c ). These tumors, however, appeared to be sensitive to a variety of treatments, including gamma radiation and aplidin treatment ( Supplementary Figures S8d and e ), suggesting opportunities for personalized therapeutic intervention (see also text below and Figures 4b, d and g).
To further determine the function of TRPM2-AS in prostate tumors, its expression was ablated in the androgen-independent PC3 PCa cell line and, as a control, the PNT1A cell line, which has no detectable TRPM2-AS ( Figure 1a ). The results of this experiment, shown in Figure 2a , indicated that the experimental siRNA AS_728 was able to deplete more than 95% of the TRPM2-AS transcripts in the PC3 cells. This ablation was coupled with apoptosis in more than 75% of the PC3 cells, whereas no significant cell death was detected in the PNT1A cell line (Figure 2b ; see the Supplementary Results and Supplementary Figure S9 for the siRNA validation experiments). Targeting of TRPM2-AS in the lower metastatic potential cell line DU145 led also to extensive apoptosis, thereby confirming the essential role of TRPM2-AS in PCa (Supplementary Figure S10 ). To verify whether siRNA AS_728 had the same effects in vivo, NOD-SCID mice were challenged with PC3 cells, and when the resultant tumors reached the size of 15 mm 2 , the mice were randomized and intratumorally injected with either the control siRNA CTRL_2 or siRNA AS_728. The injection was repeated once after 3 days. On day 7, the animals were killed, and the TRPM2-AS transcript level and the number of apoptotic cells were measured in each explanted tumor. The results indicated that the experimental siRNA was able to knock down more than half of the TRPM2-AS transcripts within the tumor, albeit less efficiently than in the in vitro experiment ( Figure 2c ). As was observed in vitro, in the in vivo-treated tumors, the reduced expression of TRPM2-AS correlated with a significant increase in the number of apoptotic cells compared with the cells treated with control siRNA (Figure 2d ). We then performed survival experiments in which NOD-SCID mice bearing subcutaneous PC3 tumors were injected biweekly with the control or experimental siRNA. As shown in Figures 2e and f, the mice treated with the experimental siRNA displayed both that is a significant decrease in tumor mass and a significant increase in survival, further highlighting the important role of TRPM2-AS in tumor biology.
Expression profiling of PC3 cells undergoing apoptosis upon ablation of TRPM2-AS expression (see Figures 2a and b) identified 1306 downregulated (3.5%) and 1218 upregulated (3.2%) transcripts ( Supplementary Table S4 ), with a heat map of the top 60 regulated transcripts displayed in Figure 3a . A large number of well-known oncological targets appeared to be ablated by TRPM2-AS silencing, as shown in Figure 3b , whereas gene ontology (GO) analysis identified 80 and 77 biological process categories that were significantly over-represented for the repressed and induced transcripts, respectively ( Supplementary  Table S4 ). Representative members of the clustered GO categories, shown in Figures 3c and d, indicated that TRPM2-AS function was required, inter alia, for the activation of transcripts involved in protein translation, chromatin modification and cell cycle progression. Cell cycle analysis using propidium iodide staining ( Figure 3e ) and 5-bromo-2-deoxyuridine incorporation (Supplementary Figure S11 ) confirmed the induction of cell cycle arrest at S phase in TRPM2-AS KO cells. Furthermore, analysis of the induced transcripts revealed the presence of several GO categories related to the unfolded protein response, in addition to the existence of both positive and negative apoptotic signals. The unfolded protein response is an evolutionarily conserved mechanism aimed at promoting cell survival by ameliorating the status of unfolded proteins but, in conditions of heavy or prolonged stress, commits the cell to programmed cell death. 25 Accordingly, several prosurvival molecules and known oncological targets, including the chaperonin HSP90B1 and the oncogenes FYN and AKT1, appeared in the list of transcripts induced by TRPM2-AS KO (Supplementary Figure S12 ), suggesting that even further scrutiny of this list may uncover new oncological targets.
GSEA identified a considerable number of lists that were significantly enriched in transcripts repressed (151 lists) or induced (257 lists) by TRPM2-AS depletion ( Supplementary Table S5 ). Among these lists, a significant overlap between transcripts regulated by several oncological drugs, including salirasib, trabectedin, adaphostin, aplidin, epoxomicin, tosedostat, tamoxifen and glucocorticoids, or treatments, including ionizing radiation and photodynamic therapy, with transcripts regulated by TRPM2-AS KO was uncovered ( Supplementary Table S6 and Figures 4a-d ). As the mechanisms of some of these treatments involve the induction of prolonged endoplasmic reticulum/ oxidative stress, we investigated whether the H 2 O 2 levels changed in the targeted PC3 cells. By measuring the peroxy green 1 fluorescence intensity of these cells, their hydrogen peroxide levels were found to be significantly increased (Figure 4e ), further indicating the role of TRPM2-AS in controlling cellular stress. Interestingly, the target transcripts of five of these treatments were also significantly regulated in the ind_TRPM2-AS_+ patients from the Sboner data set (Figure 4f ), reinforcing the rationale for treating ind_TRPM2-AS_+ patients with these therapeutics. The full list of the gene sets that are correspondingly regulated in both the targeted PC3 cells and ind_TRPM2-AS_+ patients ( Supplementary Table S7 ) confirmed the significant overlap of the two genes regulated in these two conditions (total common gene sets: 69, P = 1.4E-013) and, therefore, underlined the capability of the siRNA-treated cell line to be used as a model of TRPM2-AS function in vivo. Recent data from the literature show that TRPM2 function can be beneficial against cell death in cases of moderate oxidative stress, [26] [27] [28] whereas the prolonged high expression of TRPM2, especially in the presence of persistent oxidative stress, is lethal in different biological contexts, [29] [30] [31] [32] [33] [34] establishing a rationale for the obligation of PC3 cells to keep under tight control the needed activation of TRPM2, necessary to sustain the vigorous growth of this cell line. 35 Because several long ncRNAs negatively regulate their sense partners, 36 TRPM2-AS was examined for its contribution to the fine-tuning of TRPM2 activation in PCa. Therefore, we verified whether the mRNA level of TRPM2 was increased in the targeted PC3 cells. The results of our microarray experiment demonstrated only a mild 1.1-fold increase in the TRPM2-AS KO cells (P = 0.16), but, as it has been shown that the detection of the differential expression of fairly low-abundance transcripts, such as TRPM2, can be difficult in microarray experiments, 13 we also performed qRT-PCR experiments in the targeted PC3 cells. The results, shown in Figure 4g , indicated a >30-fold increase in TRPM2 expression upon TRPM2-AS knockdown, demonstrating the regulatory role of TRPM2-AS on the TRPM2 sense transcript in PC3 cells. (c-f) TRPM2-AS targeting in mice carrying PC3 cell xenografts. Male NOD-SCID mice were challenged subcutaneously with PC3 cells, and when the resultant tumors were approximately 15 mm 2 , the mice were intratumorally injected with AS_728 siRNA (n = 3) or CTRL siRNA (n = 3). The mice were killed 72 h after the treatment, and tumor cells were collected and tested for TRPM2-AS expression (c) and apoptosis (d). Alternatively, the mice were treated biweekly seven times and monitored for tumor growth (e) and survival (f). The data in (a-d) represent the means ± s.d. of three experiments.
DISCUSSION
Taken together, our data demonstrate a novel role for TRPM2-AS as both a prognostic marker and a therapeutic target in PCa. Several groups have used gene expression profiling to predict the aggressiveness of PCa. [37] [38] [39] [40] [41] [42] [43] However, here we show that even the quantification of a single non-coding RNA can be predictive of clinical outcome. Of course, multi-gene signature analysis is bound to be a more robust and informative test, 44 but its use in clinical routine may be more challenging than a single marker assay, especially under the current stringent Food and Drug Administration guidelines. 45 We additionally derived a gene signature, ind_TRPM2-AS, that is associated with a high level of TRPM2-AS in patients. Remarkably, even without any optimization, this signature steadily predicted the disease outcome in three independent cohorts, including patients with low-Gleason scores.
It will be interesting to compare the capability in predicting clinical outcome of this broad, 496-transcript signature to the capability of more focalized signatures, like for example those arising from stemness genes 38 or from cell cycle regulation. 40 Even the comparison with minimal 4-gene 46 or 3-gene 43 signatures could yield, in principle, some very useful prognostic information. About the data sets used for signature analysis, it should be noted that the Sboner data set contained some peculiar features that markedly differed it from more modern patient cohorts, including the Taylor data set: (1) samples had been taken by transurethral resection of the prostate rather than from prostatectomies; (2) no prostate-specific antigen screening programs were in place at the time when samples from the Sboner data set were collected;
(3) the primary endpoint in the Swedish cohort was death due to PCa rather than time to biochemical relapse, as in the Taylor data set. Taking in account these relevant differences between the AXL  NOLA2  KIAA0152  ARL2  TOP2A  HIST1H2BK  KIF20A  PRKCA  TMED10  PHACTR3  MAPBPIP  TMEM183B  C19orf53  C22orf16  PPIL1  PRELID1  TMEM183A  LGTN  HS.213061  H1F0  NCL  CHCHD4  LOC390354  E2F2  LOC347544  KRT7  CCDC92  ARAF  PPIH  FGFBP1  SLC11A2  SPINK1  HMOX1  HS.127310  PLAT  IL23A  TGM2  DUSP1  CDKN1A  PLAUR  IFIT2  FABP4  JUNB  LPXN  ESM1  TERC  LAMB3  SCG5  HS.568549  IL1RAPL1  KISS1  LOC728285  KRT34  HBEGF  CSF2  GDF15  IL1B  IL6  IL8  IL24   CTRL_1  CTRL_2  CTRL_3  CTRL_4  siRNA_1  siRNA_2  siRNA_3 Taylor and the Sboner cohorts, gene signatures that show stratification power in both are more likely to be robust. GSEA identified several relevant pathways in the signature that are disregulated in ind_TRPM2-AS patients. RNAi experiments made evident that a significant number of these pathways were correspondingly regulated in PC3 cells harboring high levels of TRPM2-AS, reinforcing the idea that this ncRNA may play a relevant role in aggressive disease. TRPM2-AS was found to be also a negative regulator of the full-length TRPM2 transcript in PC3 cells. However, its function, in keeping with the fact that sustained levels of TRPM2 are still required in these cells, 35 is more likely to prevent over-activation of the channel rather than completely abolishing its function. According to this, ablation of TRPM2 expression didn't rescue PC3 cells from the removal of TRPM2-AS (data not shown).
From a clinical point of view, it is likely that PCa patients with high levels of either TRPM2-AS or its related ind_TRPM2-AS gene signature are more prone to have a poor prognosis and should be treated. Among the treatment options, therapies aimed at increasing cellular oxidative stress and one or more of the treatment opportunities that were identified in this study should be considered. Notably, several of these treatments are currently in place but have no patient selection, leaving room for extensive therapeutic optimization. Patient selection should occur upon gene expression analysis of the biopsy sample. However, because recent studies have demonstrated that it is possible to measure ncRNA from prostate tumor cells in urine samples after digital rectal examination, 47 application of this advanced technique should, in principle, allow a minimally invasive quantification of TRPM2-AS and/or the ind_TRPM2_AS gene signature, enabling the even earlier detection of tumors that are likely to progress. Additionally, as the technology to perform in vivo systemic delivery of either siRNAs 48 or oligonucleotides 49 continues to improve, TRPM2-AS itself could become a druggable therapeutic target. 
MATERIALS AND METHODS

Patient samples
For the data displayed in Figure 1a , detailed information is available in the Supplementary Figure S1 . For the samples from the University of Padua and San Raffaele Hospital, written informed consent was obtained from the patients. Seventeen samples were from the TissueScan Prostate PCR array (HPRT101, Origene, Rockville, MD, USA): 7 normal tissues and 10 tumor samples. From this array, we included all of the normal tissue samples and all of the tumor tissue samples that had at least 60% tumor tissue. Detailed pathology reports of these samples can be found at Origene's website (http://www.origene.com/assets/documents/TissueScan/HPRT101.xls). As these samples were obtained commercially without any accompanying patient-identifying data, they are considered 'exempt' from informed consent according to HHS guidelines.
Cell lines
PNT1A, a non-malignant cell line established by immortalization and cloning of normal prostate epithelial cells with SV40 large T antigen, was kindly provided by professor P. Limonta, University of Milan (Milan, Italy). PC3 androgen-independent PCa cells were purchased from the American Tissue Culture Collection. PNT1A and PC3 cell lines were routinely grown in RPMI 1640 supplemented with 10% fetal bovine serum, glutamine (1 mmol/l), and antibiotics (100 IU/ml penicillin G sodium and 100 µg/ml streptomycin sulfate). Cells were incubated at 37°C in 5% CO 2 .
RNA interference
Synthetic 21-nt RNAs were purchased from MWG (www.mwg-biotech.com) in deprotected, desalted and annealed form, whereas STEALTH siRNAs were obtained from Invitrogen. All siRNA sequence were subjected to BLAST search to confirm the absence of a significant similarity to any known additional transcript in the human genome. For in vitro targeting, siRNAs were transfected in the human PCa cell line PC3 or in the control prostate epithelial cell line PNT1A using the transfection reagent Lipofectamine RNAiMax from Invitrogen, Carlsbad, CA, USA. Final siRNA concentration in the medium was 5 nM. Cells were harvested for RNA extraction at 48 h, whereas they were harvested after 65 h for determination of apoptosis by fluorescence-activated cell sorting analysis. siRNAinduced apoptosis was assessed using Anx-V FITC apoptosis detection kit (Immunostep, Salamanca, Spain). Apoptotic cells were identified as Annexin V/propidium iodide-positive cells following the manufacturer's instructions. For in vivo targeting of TRPM2-AS expression in mice, agematched NOD CB15 males were injected subcutaneously with one million PC3 cells. Tumors, usually visible 20-40 days after cell inoculation, were injected with either AS_728 or CTRL_2 siRNAs, complexed with Invivofectamine (Invitrogen) according to the manufacturer's instructions. siRNAs were diluted at 2 µg/µl and injected at a final concentration of 0.5 µl per each mm 3 of tumor size. Tumors were surgically explanted into Dulbeccos modified Eagles medium containing 0.15% collagenase. Animals were killed when tumors became large, ulcerated or necrotic. siRNA used for ablating TRPM2-AS expression were as follows: AS_734, 5′-CCACUUACUC AUCCAAGAA-3′ and its negative control CTRL_1, 5′-AGGUAGUGUAAUCGC CUUG-3′, AS_728, 5′-CACCAGCCACUUACUCAUCCAAGAA-3′ and its negative control CTRL_2, 5′-UAAAUGUACUGCGCGUGGAGAGGAA-3′.
Analysis of microarray data
Total RNA was extracted from PC3 cells by using RNeasy columns (Qiagen, Venlo, Netherlands). Quantity and integrity of the extracted RNA was assessed by NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and by Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Synthesis of cDNA and biotinylated cRNA was carried out using the Illumina TotalPrep RNA Amplification Kit (Illumina, San Diego, CA, USA) using 500 ng of total RNA. Hybridization was performed in quadruplicates, using the HumanHT-12 v3 Expression Beadchip (Illumina). Data were normalized using the rank invariant normalization algorithm implemented on the Illumina BeadStudio software (Illumina), using all probes on the array for the extraction of the rank invariant set of transcripts. After normalization, the expression data set was further corrected by setting the bottom threshold signal to 140. This value was estimated from background noise obtained using Illumina negative controls, representing an estimation of both the image background and the signals derived from non-specific binding or cross-hybridization. Differential expression of transcripts was assessed using the limma package (http://www.bioconductor.org/packages/release/bioc/html/ limma.html). Specifically, 1306 upregulated and 1218 downregulated transcripts were selected using a corrected P-value threshold of 0.01 and a fold-change threshold of 1.5. GO category analysis for non-random enrichments (Po 0.005) of the genes regulated in PC3 cells was performed using the GO::TermFinder program. 50 Gene set enrichment analysis of the differentially expressed transcripts was performed using the GenePattern suite of programs (www.broadinstitute.org/cancer/software/genepattern). Default search parameters were used, except that 10 000 permutations were used, the 'collapse data set' parameter was set to 'false', the 'permutation type' parameter was set to 'gene set' and the maximum set size was set to 1000. Significance cutoff was the following: P-value ⩽ 0.001, false discovery rate ⩽ 0.01. Microarray data have been deposited in GEO with accession code GSE40687.
Real-time quantification
qRT-PCR experiments for quantifying Beta-actin, TRPM-AS and the fulllength TRPM2 sense transcript (TRPM2-FL) transcripts were performed as described. 15 H 2 O 2 measurement H 2 O 2 production was assessed 54 h after transfection of PC3 cells with the control or the experimental siRNA. Upon harvesting, cells were washed and incubated for 30 min at room temperature with 0.5 µg/ml propidium iodide, 5 mM Peroxy-Green 1. 51 After extensive washing, samples were analyzed by FACSCalibur and data analyzed by the CellQuestPRO (BD Biosciences, San Jose, CA, USA) or FCS express (De Novo Software, Los Angeles, CA, USA) software. Only living cells, gated according to scatter parameters, were used for the analysis.
Cell cycle profile PC3 cells were seeded and transfected with either the control CTRL_2 siRNA or the experimental AS_728 siRNA as previously described. After 48 h, cells were pulsed with 33 micromolar 5-bromo-2-deoxyuridine (Sigma) for 30 min. Cells were then harvested and fixed in phosphatebuffered saline 70% EtOH. Fixed cells were treated with 2 N HCl for 25 min and 5-bromo-2-deoxyuridine incorporation was detected using an anti-5-bromo-2-deoxyuridine (Sigma, St. Louis, MO, USA) primary antibody and fluorescein isothiocyanate-coniugated secondary antibody (Sigma). Cells were then resuspended in propidium iopdide (2.5 µg/ml)/RNaseA overnight at 4°C. fluorescence-activated cell sorting analysis was performed using FACSCanto flow cytometer (BD Biosciences) and data were analyzed using ModFit LT (Verity Software House, Topsham, ME, USA) and CellQuestPRO software (BD Biosciences).
Analysis of public RNA-seq data
Sequences were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo) and dbGAP (http://www.ncbi.nlm.nih.gov/gap) repository databases. In detail, following data sets were retrieved from GEO: GSE24283, GSE22260, GSE29155, GSE25183. Controlled access data were authorized from the appropriate Data Access Committee for the following two dbGAP data sets: phs000310 and phs000311. Reads for TRPM2-AS transcript (EU362988) were identified by aligning the sequence against the short-sequence reads using the BLASTN program. For consistency with qRT-PCR experiments, RNA-seq data were normalized across samples by querying the same data set with the portion 701-800 of beta actin gene (ACTB, NM_001101) and reporting counts as tags per one-million 701-800 nts ACTB reads. However, normalization using either the human glyceraldehyde 3-phosphate dehydrogenase gene (NM_002046, nts 701-800) or reads per kilobase per million mapped reads 52 gave similar results (data not shown). E-value cutoff for BLASTN alignments was 1E-03.
Analysis of public microarray data
TRPM2-AS expression within the Taylor data set was determined using the intensities of the 12 probes corresponding to the TRPM2-AS transcript on Affymetrix Human Exon 1.0 ST arrays. The raw data were backgroundsubtracted and RMA-normalized at the probe level using the R xps package (version 1.12.1) from Bioconductor (http://www.bioconductor.org/ packages/release/bioc/html/xps.html). The ancillary ROOT package (version 5.27.04; http://root.cern.ch) was used. To calculate the differential expression of TRPM2-AS, we employed a probe selection algorithm to obtain a subset of probes with highly correlated intensities. 53 As a result, a subset of three probes was selected (Probe IDs: #1778365, #2739080 and #5923269). The TRPM2-AS fold change calculation in tumor vs healthy samples was accomplished by averaging the fold change of each of the selected probes, with the average TRPM2-AS level in the healthy samples arbitrarily set to 1. For the identification of transcripts showing differential expression in TRPM2-AS depleted vs rich samples, normalized mRNA expression data were downloaded from the cBio Cancer Genomics Portal (http://cbio.mskcc.org/cancergenomics/prostate/data/MSKCC_PCa_mRNA_ data.zip). The clinical parameters of the patients, including their Gleason score, prostate-specific antigen level, androgen receptor activation status and metastases occurrence, were obtained from Taylor et al. 16 Androgen receptor activation was determined through the identification of mutations or gene amplification within the androgen receptor gene. The TMPRSS2-ERG fusion status was derived from aCGH data reported in the clinical annotation table provided on the cBio portal website (http://cbio. mskcc.org/cancergenomics/prostate/data/).
A step-by-step protocol was followed for the analysis of the ind_TRPM2-AS signature as a prognostic marker in order to satisfy the conditions of a 'prospective-retrospective study'. 54 To check for the enrichment of the ind_TRPM2-AS signature in patients from the Taylor and Sboner (GSE16560) data sets, a previously described method was used. 55 Briefly, upon downloading the normalized data, we calculated the mean expression level for each transcript across all of the samples in the data set and scored, for each sample, the transcripts in the ind_TRPM2-AS signature whose expression was at least 1.5 times above or below the mean expression. We then assessed, for each sample, the fraction of overor under-expressed transcripts, calculating a P-value according to the hypergeometric distribution using the following thresholds: (a) P ⩽ 0.05, samples positive for the ind_TRPM2-AS signature (ind_TRPM2-AS_+); (b) P>0.9, samples negative for the ind_TRPM2-AS signature (ind_TRPM2-AS_ − ). The enrichment in the ind_TRPM2-AS signature in patients from the Glinsky data set was similarly determined, except that the normalized probe set intensities and pertinent clinical parameters were obtained from Ding et al. 46 The numbers of transcripts from the ind_TRPM2-AS signature that were present in the Taylor, Sboner and Glinsky data sets were 496 (100%), 172 (35%) and 303 (61%), respectively. The clinical parameters for the patients in the Sboner data set were taken from the relative GEO entry. Default search parameters were used for the GSEA analysis, except that 10 000 permutations were used and the 'collapse data set' parameter was set to 'false'. The significance cutoffs were: P ⩽ 0.02 and false discovery rate ⩽ 0.15. The computational procedures needed to reproduce the microarray analyzes, along with the pertinent documentation and data sets, are available at https://www.dropbox.com/s/phjn2engr3nrjnh/Script-sAndData.tar.gz
Statistical analysis
Statistical tests used were as follows: the unpaired two-tailed Student's t-test for continuous variables, with or without Welch correction for cases in which the variances of the populations were significantly different; the hypergeometric test and the Fisher's exact test for discrete variables. Additionally, the log-rank test and the Cox proportional hazards regression model were used to test for differences in survival.
